Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder

Bipolar Disorders

Volumn 14, Issue 7, 2012, Pages 719-726

  Olsson, Sara K ^a   Sellgren, Carl ^a   Engberg, Göran ^a   Landén, Mikael ^a,b   Erhardt, Sophie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cerebrospinal fluid; Kynurenate; Lumbar puncture; Mania; Psychosis

Indexed keywords

KYNURENIC ACID; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; OLANZAPINE; PROPIOMAZINE; QUETIAPINE; VALPROIC ACID;

ADULT; ARTICLE; BEHAVIOR; BIPOLAR I DISORDER; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; LIFESPAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL PATIENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PSYCHOSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RISK; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; KYNURENIC ACID; LOGISTIC MODELS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84868092047     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12009     Document Type: Article

References (62)

1. Sathyasaikumar KV, Stachowski EK, Wonodi I et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 2011; 37: 1147-1156.
2. Linderholm KR, Skogh E, Olsson SK et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012; 38: 426-432.
3. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001; 313: 96-98.
4. Nilsson LK, Linderholm KR, Engberg G et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005; 80: 315-322.
5. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-530.
6. Olsson SK, Samuelsson M, Saetre P et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci 2010; 35: 195-199.
7. Goldberg JF, Chengappa KN. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord 2009; 11 (Suppl. 2): 123-137.
8. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963; 20: 140-144.
9. Murphy DL, Brodie HK, Goodwin FK, Bunney WE Jr. Regular induction of hypomania by l-dopa in 'bipolar' manic-depressive patients. Nature 1971; 229: 135-136.
10. Parsons CG, Danysz W, Quack G et al. Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 1997; 283: 1264-1275.
11. Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989; 52: 1319-1328.
12. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001; 21: 7463-7473.
13. Ganong AH, Cotman CW. Kynurenic acid and quinolinic acid act at N-methyl-d-aspartate receptors in the rat hippocampus. J Pharmacol Exp Ther 1986; 236: 293-299.
14. Birch PJ, Grossman CJ, Hayes AG. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 1988; 154: 85-87.
15. Nilsson LK, Linderholm KR, Erhardt S. Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. J Neural Transm 2006; 113: 557-571.
16. Olsson SK, Andersson AS, Linderholm KR et al. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol 2009; 12: 501-512.
17. Linderholm KR, Andersson A, Olsson S et al. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology 2007; 53: 918-924.
18. Erhardt S, Engberg G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 2002; 175: 45-53.
19. Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G. Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci 2008; 83: 170-175.
20. Schwieler L, Erhardt S, Nilsson L, Linderholm K, Engberg G. Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons-possible involvement of endogenous kynurenic acid. Synapse 2006; 59: 290-298.
21. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 2004; 56: 255-260.
22. Gogos A, van den Buuse M, Rossell S. Gender differences in prepulse inhibition (PPI) in bipolar disorder: men have reduced PPI, women have increased PPI. Int J Neuropsychopharmacol 2009; 12: 1249-1259.
23. Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull 2010; 36: 211-218.
24. Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009; 23: 91-101.
25. Shepard PD, Joy B, Clerkin L, Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 2003; 28: 1454-1462.
26. Chess AC, Landers AM, Bucci DJ. l-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res 2009; 201: 325-331.
27. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007; 33: 797-804.
28. Chess AC, Bucci DJ. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res 2006; 170: 326-332.
29. Abbott A, Roberts BM, Turner L et al. Inhibition of kynurenine aminotransferase II (KATII) protects against ketamine-induced cognitive impairment and improves spatial working memory. Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience; Program no 472.18 [online], 2010. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8a4c8a45-e785-469e-b151-2e92be77432a&cKey=dbeec220-606a-4a7e-a2c3-b11af317777a&mKey={E5D5C83F-CE2D-4D71-9DD6-FC7231E090FB} [accessed 18 September 2012].
30. Ekman CJ, Lind J, Ryden E, Ingvar M, Landen M. Manic episodes are associated with grey matter volume reduction-a voxel-based morphometry brain analysis. Acta Psychiatr Scand 2010; 122: 507-515.
31. Sachs GS, Thase ME, Otto MW et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028-1042.
32. First MB, Spitzer RI, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute, 2002.
33. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl. 20): 22-33.
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
35. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
36. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
37. Swartz KJ, Matson WR, MacGarvey U, Ryan EA, Beal MF. Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. Anal Biochem 1990; 185: 363-376.
38. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006; 1074: 25-37.
39. Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, Kalina P. Age-related increase of kynurenic acid in human cerebrospinal fluid-IgG and beta2-microglobulin changes. Neurosignals 2005; 14: 126-135.
40. Nilsson LK, Nordin C, Jonsson EG, Engberg G, Linderholm KR, Erhardt S. Cerebrospinal fluid kynurenic acid in male and female controls-correlation with monoamine metabolites and influences of confounding factors. J Psychiatr Res 2007; 41: 144-151.
41. Olsson SK, Larsson MK, Erhardt S. Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice. J Neural Transm 2012; 119: 155-163.
42. Anand A, Verhoeff P, Seneca N et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000; 157: 1108-1114.
43. Adler CM, Malhotra AK, Elman I et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999; 156: 1646-1649.
44. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135: 1081-1084.
45. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201-225.
46. Malhotra AK, Pinals DA, Adler CM et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-150.
47. Kegeles LS, Abi-Dargham A, Zea-Ponce Y et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000; 48: 627-640.
48. Beneyto M, Meador-Woodruff JH. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008; 33: 2175-2186.
49. Breier A, Su TP, Saunders R et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569-2574.
50. Laruelle M, Abi-Dargham A, van Dyck CH et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-9240.
51. Abi-Dargham A, Gil R, Krystal J et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155: 761-767.
52. Bendikov I, Nadri C, Amar S et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr Res 2007; 90: 41-51.
53. Roberts RC, Du F, McCarthy KE, Okuno E, Schwarcz R. Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: a light and electron microscopic study. J Comp Neurol 1992; 326: 82-90.
54. Guillemin GJ, Cullen KM, Lim CK et al. Characterization of the kynurenine pathway in human neurons. J Neurosci 2007; 27: 12884-12892.
55. Kiss C, Ceresoli-Borroni G, Guidetti P, Zielke CL, Zielke HR, Schwarcz R. Kynurenate production by cultured human astrocytes. J Neural Transm 2003; 110: 1-14.
56. -/- mice. Int J Neuropsychopharmacol 2010; 13: 475-485.
57. Holtze M, Asp L, Schwieler L, Engberg G, Karlsson H. Induction of the kynurenine pathway by neurotropic influenza A virus infection. J Neurosci Res 2008; 86: 3674-3683.
58. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
59. King NJ, Thomas SR. Molecules in focus: indoleamine 2, 3-dioxygenase. Int J Biochem Cell Biol 2007; 39: 2167-2172.
60. Söderlund J, Olsson SK, Samuelsson M et al. Elevation of cerebrospinal fluid interleukin-1beta in bipolar disorder. J Psychiatry Neurosci 2011; 36: 114-118.
61. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 2006; 113: 1355-1365.
62. Kocki T, Wielosz M, Turski WA, Urbanska EM. Enhancement of brain kynurenic acid production by anticonvulsants-novel mechanism of antiepileptic activity? Eur J Pharmacol 2006; 541: 147-151.